gvtcx

NHS National Framework for Tocilizumab - March 2024

NHS England Published 8 Apr 2024 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£150,000,000
Statuscomplete
Category (CPV) 33600000
Deadline3 Jan 2024
Procedureopen
OCIDocds-h6vhtk-041db8

Awards (2)

This procurement was awarded to 2 suppliers. Values shown are per-award; the notice total is £150,000,000.

SupplierValueDateStatus
Fresenius Kabi Limited shared · · active
Roche Products Ltd shared · · active

description

Project Title: NHS National Framework for Tocilizumab - March 2024<br/> <br/>Offer reference number: CM/PHR/23/5702<br/><br/>CM/PHR/23/5702/01 NHS Framework for Tocilizumab LONDON and SOUTH OF ENGLAND. Period of framework: 1 March 2024 to 28 February 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. <br/><br/>CM/PHR/23/5702/02 NHS Framework for Tocilizumab NORTH OF ENGLAND and MIDLANDS AND EAST. Period of framework: 1 March 2024 to 28 February 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

3 notices published against this procurement.

PublishedTypeRegimeNotice
29 Nov 2023 Contract notice (F02) Earlier regulations 035227-2023
29 Nov 2023 Tender (tender) · 1b4eb68c-69ac-49ba-91e2-efcf1573ca5e-702902
8 Apr 2024 Contract award notice (F03) Earlier regulations 011334-2024

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.